Skip to content

Study · Randomized controlled trial · n = 30 · 2015

4 results

Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial.

Muin DA, Wolzt M, Marculescu R, Sheikh Rezaei S, Salama M, Fuchs C, Luger A, Bragagna E, Litschauer B, Bayerle-Eder M

Fertility and sterility4 Jul 2015Cited by 30 (Europe PMC)

PMID26151620 (opens in a new tab)DOI10.1016/j.fertnstert.2015.06.010 (opens in a new tab)PepBankPUB-26151620
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with sexual dysfunction, the FSFI score rose by 26% after oxytocin and 31% after placebo, with no statistically significant treatment effect.

    In plain wordsIn women with sexual dysfunction, sexual function scores rose after both oxytocin and placebo, with no significant difference between them.

    Peptide
    Oxytocin
    Outcome
    No significant changeFemale Sexual Function Index (FSFI) score
    Study

    n = 30

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    32 IU · intranasal · 8 weeksAs given in this study (human).

    Measurements

    FSFI score change
    26%
    oxytocin
    FSFI score change
    31%
    placebo

    Source sentences

    Summary
    After oxytocin and placebo, the FSFI score increased by 26% and 31%, SQOL-F score by 144% and 125%, and SIDI-F score by 29% and 23%, respectively (repeated measures analysis of variance between groups).
    4 context sentences
    Summary · context
    There was no statistically significant treatment, sequence (placebo first/second), or interaction effect.
    Summary · context
    Randomized, prospective, double-blind, placebo-controlled, crossover trial with duration of 22 weeks.
    Summary · context
    Thirty pre-and postmenopausal women with sexual dysfunction.
    Summary · context
    intranasal oxytocin (32 IU) or placebo self-administered by women within 50 minutes before sexual intercourse; after a washout period of 2 weeks, crossover with patients switched to the alternate group for another 8 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with sexual dysfunction, the SQOL-F score rose by 144% after oxytocin and 125% after placebo, with no statistically significant treatment effect.

    In plain wordsIn women with sexual dysfunction, sexual quality of life rose after both oxytocin and placebo, with no significant difference between them.

    Peptide
    Oxytocin
    Outcome
    No significant changeSexual Quality of Life-Female (SQOL-F) score
    Study

    n = 30

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    32 IU · intranasal · 8 weeksAs given in this study (human).

    Measurements

    SQOL-F score change
    144%
    oxytocin
    SQOL-F score change
    125%
    placebo

    Source sentences

    Summary
    After oxytocin and placebo, the FSFI score increased by 26% and 31%, SQOL-F score by 144% and 125%, and SIDI-F score by 29% and 23%, respectively (repeated measures analysis of variance between groups).
    4 context sentences
    Summary · context
    There was no statistically significant treatment, sequence (placebo first/second), or interaction effect.
    Summary · context
    Randomized, prospective, double-blind, placebo-controlled, crossover trial with duration of 22 weeks.
    Summary · context
    Thirty pre-and postmenopausal women with sexual dysfunction.
    Summary · context
    intranasal oxytocin (32 IU) or placebo self-administered by women within 50 minutes before sexual intercourse; after a washout period of 2 weeks, crossover with patients switched to the alternate group for another 8 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with sexual dysfunction, the SIDI-F score rose by 29% after oxytocin and 23% after placebo, with no statistically significant treatment effect.

    In plain wordsIn women with sexual dysfunction, sexual interest and desire scores rose after both oxytocin and placebo, with no significant difference between them.

    Peptide
    Oxytocin
    Outcome
    No significant changeSexual Interest and Desire Inventory-Female (SIDI-F) score
    Study

    n = 30

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    32 IU · intranasal · 8 weeksAs given in this study (human).

    Measurements

    SIDI-F score change
    29%
    oxytocin
    SIDI-F score change
    23%
    placebo

    Source sentences

    Summary
    After oxytocin and placebo, the FSFI score increased by 26% and 31%, SQOL-F score by 144% and 125%, and SIDI-F score by 29% and 23%, respectively (repeated measures analysis of variance between groups).
    4 context sentences
    Summary · context
    There was no statistically significant treatment, sequence (placebo first/second), or interaction effect.
    Summary · context
    Randomized, prospective, double-blind, placebo-controlled, crossover trial with duration of 22 weeks.
    Summary · context
    Thirty pre-and postmenopausal women with sexual dysfunction.
    Summary · context
    intranasal oxytocin (32 IU) or placebo self-administered by women within 50 minutes before sexual intercourse; after a washout period of 2 weeks, crossover with patients switched to the alternate group for another 8 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with sexual dysfunction, the FSDS score fell by 36% after oxytocin and 45% after placebo, with no statistically significant treatment effect.

    In plain wordsIn women with sexual dysfunction, sexual distress scores fell after both oxytocin and placebo, with no significant difference between them.

    Peptide
    Oxytocin
    Outcome
    No significant changeFemale Sexual Distress Scale (FSDS) score
    Study

    n = 30

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    32 IU · intranasal · 8 weeksAs given in this study (human).

    Measurements

    FSDS score change
    36%
    oxytocin
    FSDS score change
    45%
    placebo

    Source sentences

    Summary
    After oxytocin and placebo, the FSDS score decreased by 36% and 45%, respectively (repeated measures analysis of variance between groups).
    4 context sentences
    Summary · context
    There was no statistically significant treatment, sequence (placebo first/second), or interaction effect.
    Summary · context
    Randomized, prospective, double-blind, placebo-controlled, crossover trial with duration of 22 weeks.
    Summary · context
    Thirty pre-and postmenopausal women with sexual dysfunction.
    Summary · context
    intranasal oxytocin (32 IU) or placebo self-administered by women within 50 minutes before sexual intercourse; after a washout period of 2 weeks, crossover with patients switched to the alternate group for another 8 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT02229721

Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women

Medical University of Viennan = 30Jun 2012 to Oct 2013

Female Sexual Dysfunction

Trial pageClinicalTrials.govUpdated 1 Sept 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.